Vaccentis’ lead product VCC-001, which is in late-stage clinical development to treat non-metastatic renal cell carcinomas post nephrectomy. Vaccentis’ proprietary production methodology reduces complexity and allows for a three to four week vaccine delivery time, significantly shorter than normally seen with other personalized biologics.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze